Gallegos-Villalobos Angel, García-López Fernando, Escalada Carmen, Ortiz Juan J, Cardona Jorge, Medina Amparo, Portolés José
Nefrologia. 2014 May 21;34(3):317-22. doi: 10.3265/Nefrologia.pre2014.Jan.12442. Epub 2014 Feb 10.
Thyroid carcinoma is a neoplasia with a higher incidence in patients with chronic kidney disease. In recent years advances have been made in diagnostic and therapeutic trials. Dialysis patients are a particular group, their cancer being detected indirectly in the study of secondary hyperparathyroidism and during the study prior to renal transplantation. Thyroidectomy is the definitive treatment, but in patients with risk of recurrence, ablative therapy is required using radioactive iodine I-131, which is predominantly eliminated by renal excretion, therefore its use in patients on dialysis poses a problem in terms of dosage. Two cases are presented of patients on haemodialysis undergoing radioablation with radioactive iodine I-131, which with multidisciplinary treatment had the expected results in the patients.
甲状腺癌是一种在慢性肾病患者中发病率较高的肿瘤。近年来，诊断和治疗试验取得了进展。透析患者是一个特殊群体，他们的癌症在继发性甲状旁腺功能亢进的研究以及肾移植术前的检查中被间接发现。甲状腺切除术是确定性治疗方法，但对于有复发风险的患者，需要使用放射性碘I-131进行消融治疗，而放射性碘I-131主要通过肾脏排泄清除，因此在透析患者中使用时，剂量方面存在问题。本文介绍了两例接受放射性碘I-131放射性消融治疗的血液透析患者，经过多学科治疗，患者取得了预期效果。
